CSOPS/J&J Continuous Pharma Manufacturing Line Advances to Commercial Production

Achievement date: 
2013
Outcome/accomplishment: 

The NSF-funded Engineering Research Center (ERC) for Structured Organic Particulate Systems (CSOPS) at Rutgers, The State University of New Jersey and the University of Puerto Rico at Mayaguez (UPRM), in collaboration with Johnson & Johnson (J&J), have successfully commercialized a direct compression manufacturing line for Prezista, a drug used to treat HIV infections, at the J&J plant in Gurabo, Puerto Rico.

Impact/benefits: 

Many companies, including several of CSOPS’s industrial partners, have expressed interest in continuous manufacturing technology because it promises increased speed and efficiency, as well as improved consistency in manufacturing tablets, capsules, and other pharmaceutical products. This project is an example of the complete transfer of technology from academia to industry.

On March 28, 2012, NSF Director Subra Suresh testified before the House Appropriations Committee on “NSF’s Role in Advanced Manufacturing.” He described the ERC Program, using CSOPS as an example of how the ERCs support manufacturing how CSOPS in particular is revolutionizing the American pharmaceutical industry.

Explanation/Background: 

The recently completed facility was developed in close collaboration between CSOPS, J&J, and member companies Glatt Air and K-Tron. It took three years to complete and was funded through a translational research award from the ERC Program and a $12.5 million commitment from CSOPS member company J&J. The line is a virtual twin of the line assembled by Eric Jayjock, a Rutgers post doc, and his team that features fully automated processing and real-time operations control.

A second phase of the project for other projects is currently under negotiation and a roller compaction line at Purdue is nearing completion. Ten major pharmaceutical companies are collaborating with CSOPS or are planning to leverage the technology resulting from its research.